Literature DB >> 24127186

Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis.

Nathalie Scamuffa1, Fatma Sfaxi, Jia Ma, Claude Lalou, Nabil Seidah, Fabien Calvo, Abdel-Majid Khatib.   

Abstract

Proteolytic maturation of various precursor proteins by the proprotein convertase Furin is now considered as a crucial step in tumor progression and metastasis. Here, we report the repression of the malignant and metastatic potential of carcinoma cells by the prodomain region of Furin (ppFurin), a naturally occurring inhibitor of this convertase. Overexpression of ppFurin in carcinoma cells in a stable manner significantly reduced their convertase activity and ability to mediate processing of the Furin cancer-related substrates platelet-derived growth factor (PDGF)-A and insulin-like growth factor-I receptor precursors. Unprocessed platelet-derived growth factor-A produced by ppFurin expressing cells failed to induce the activation of Akt in the platelet-derived growth factor receptor-expressing cells NIH BALB/c-3T3 and treatment of ppFurin expressing cells with insulin-like growth factor-I failed to induce Akt phosphorylation, compared with controls. The malignant potential of ppFurin expressing cells was significantly reduced as revealed by the loss of anchorage-independent growth and survival that associated their increased chemosensitivity. In vivo, comparative studies revealed that expression of ppFurin in the carcinoma cells MDA-MB-231 and CT-26 cells inhibited tumor growth when subcutaneously inoculated in nude mice. The use of an experimental liver colorectal metastasis model revealed the reduced ability of metastatic carcinoma CT-26 cells to colonize the liver in response to intrasplenic/portal inoculation. Further analyses revealed reduced Furin activity in tumors derived from intrasplenic inoculated mice with ppFurin expressing CT-26 cells. This finding highlights the role of Furin in the malignant and metastatic potential of tumor cells and suggests the possible consideration of using its naturally occurring inhibitor ppFurin in anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24127186     DOI: 10.1093/carcin/bgt345

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  12 in total

1.  The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He; Lieven Thorrez; Geraldine Siegfried; Sandra Meulemans; Serge Evrard; Sabine Tejpar
Journal:  Oncogene       Date:  2020-03-06       Impact factor: 9.867

2.  Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism.

Authors:  Sven O Dahms; Marcelino Arciniega; Torsten Steinmetzer; Robert Huber; Manuel E Than
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-19       Impact factor: 11.205

Review 3.  The proprotein convertase furin in cancer: more than an oncogene.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He
Journal:  Oncogene       Date:  2022-01-07       Impact factor: 8.756

4.  Mechanism of Fine-tuning pH Sensors in Proprotein Convertases: IDENTIFICATION OF A pH-SENSING HISTIDINE PAIR IN THE PROPEPTIDE OF PROPROTEIN CONVERTASE 1/3.

Authors:  Danielle M Williamson; Johannes Elferich; Ujwal Shinde
Journal:  J Biol Chem       Date:  2015-07-30       Impact factor: 5.157

5.  ELA/APELA precursor cleaved by furin displays tumor suppressor function in renal cell carcinoma through mTORC1 activation.

Authors:  Fabienne Soulet; Clement Bodineau; Katarzyna B Hooks; Jean Descarpentrie; Isabel Alves; Marielle Dubreuil; Amandine Mouchard; Malaurie Eugenie; Jean-Luc Hoepffner; Jose J López; Juan A Rosado; Isabelle Soubeyran; Mercedes Tomé; Raúl V Durán; Macha Nikolski; Bruno O Villoutreix; Serge Evrard; Geraldine Siegfried; Abdel-Majid Khatib
Journal:  JCI Insight       Date:  2020-07-23

6.  FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice.

Authors:  Gopala K Yakala; Hector A Cabrera-Fuentes; Gustavo E Crespo-Avilan; Chutima Rattanasopa; Alexandrina Burlacu; Benjamin L George; Kaviya Anand; David Castaño Mayan; Maria Corlianò; Sauri Hernández-Reséndiz; Zihao Wu; Anne M K Schwerk; Amberlyn L J Tan; Laia Trigueros-Motos; Raphael Chèvre; Tricia Chua; Robert Kleemann; Elisa A Liehn; Derek J Hausenloy; Sujoy Ghosh; Roshni R Singaraja
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

7.  Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth.

Authors:  Jeroen Declercq; Bas Brouwers; Vincent P E G Pruniau; Pieter Stijnen; Krizia Tuand; Sandra Meulemans; Annik Prat; Nabil G Seidah; Abdel-Majid Khatib; John W M Creemers
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

8.  Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases.

Authors:  Fatma Sfaxi; Nathalie Scamuffa; Claude Lalou; Jia Ma; Peter Metrakos; Géraldine Siegfried; Hermann Ragg; Andreas Bikfalvi; Fabien Calvo; Abdel-Majid Khatib
Journal:  Oncotarget       Date:  2014-06-30

9.  Effect of Furin inhibitor on lung adenocarcinoma cell growth and metastasis.

Authors:  Yong-Chao Ma; Wen-Juan Fan; Shu-Mei Rao; Li Gao; Zhan-Yu Bei; Song-Tao Xu
Journal:  Cancer Cell Int       Date:  2014-05-22       Impact factor: 5.722

10.  The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.

Authors:  Patricia Jaaks; Valentina D'Alessandro; Nicole Grob; Sina Büel; Katarina Hajdin; Beat W Schäfer; Michele Bernasconi
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.